“Celine brings a wealth of experience in advancing radiopharmaceutical precision oncology treatments from early development through to regulatory approval. As she steps into the leadership of our medical team, her expertise will be instrumental in progressing our pipeline and delivering new treatment options for patients,” said Dr. Andrew Cavey, Chief Executive Officer of ITM.